5-azacytidine
Germ Cell Tumors
National Cancer Institute (NCI)Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Germ Cell Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide M.D. Anderson Cancer Center | Phase 3 | BB |
ETOPOSIDE Nabil Adra | Phase 3 | BB |
Pembrolizumab Hoffmann-La Roche | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Hoffmann-La Roche | Phase 3 | BB |
Carboplatin Hoffmann-La Roche | Phase 3 | BB |
View all 48 →
Same molecule, other indications
5-azacytidine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →